Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Experience with post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis in HLA-matched related donor HSCT in pediatric and adult patients. evidence of real-life outcomes from a Latin American transplant center.

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAraceli Leal AlanisUniversidad Metropolitana de Monterrey

Discussion

Loading...

Member takes

Implication

Real-life evidence shows PTCy effectively reduces GVHD in pediatric and adult patients undergoing HSCT.

Key Points

  • To evaluate the efficacy of post-transplant cyclophosphamide for GVHD prophylaxis in HLA-matched related donor HSCT.
  • Descriptive analysis of outcomes in pediatric and adult patients
  • Overall survival and relapse-free survival assessed by Kaplan–Meier method
  • Evaluated cumulative incidence of graft-versus-host disease (GVHD)
  • One- and two-year OS rates were 69% and 62%, respectively; RFS rates were 71% and 54%.
  • GVHD occurred in 27% of patients; chronic GVHD was 24% at two years.
  • Non-relapse mortality was 9%, highlighting effective prophylaxis.

Cite This Study

Araceli Leal Alanis (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd02https://doi.org/10.1182/blood-2025-7717
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use Of Post Transplant Cyclophosphamide In Matched Related And Unrelated Donor Hematopoietic Stem Cell Transplant For Benign Hematological Disorders2024
  2. 2Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after “Allogeneic Stem Cell Transplantation from 9/10HLA Matched Unrelated Donor’’ with Standard Graft Versus Host Disease Prophylaxis after “10/10HLA Matched Relative Donor’’2024 · 1 citations
  3. 3Post‐transplantation cyclophosphamide versus conventional graft‐versus‐host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation2016 · 85 citations
  4. 4Post-Transplant Cyclophosphamide versus Anti-Thymocyte Globulin in Patients with Hematological Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical and Matched Unrelated Donors: A Real-Life Experience2024 · 1 citations
  5. 5Post-transplant cyclophosphamide as graft-versus-host disease prophylaxis for matched related donor hematopoietic stem cell transplantation in acute leukemia: a systematic review and meta-analysis.2026